Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2017
At a glance
- Drugs INS 1007 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms Willow study
- Sponsors Insmed
- 15 Aug 2017 Planned End Date changed from 1 Apr 2020 to 1 Jun 2020.
- 15 Aug 2017 Planned primary completion date changed from 7 Jan 2020 to 1 Jun 2020.
- 12 Jul 2017 Status changed from planning to not yet recruiting.